- Acumen Powered by Robins Kaplan LLP™
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
July 21, 2021Benchmark Litigation Names Patrick Arenz and Aaron Fahrenkrog to its 40 & Under Hot List in 2021
-
July 20, 2021Five Robins Kaplan Firm Members Recognized by Minnesota Lawyer
-
July 19, 2021Robins Kaplan Attorneys Recognized as 2021 Minnesota Super Lawyers and Rising Stars
-
July 26, 2021Tee It up for the Troops
-
August 5, 2021Domesticating an Out of State Judgment in The State of Florida
-
August 6, 2021Mastering the Deposition: 30(b)(6) Deposition Strategies and Updates 2021
-
July 15, 2021Biotechnology & Trade Secret Protection
-
July 6, 2021'Abuse of dominance': Was this what Congress originally intended for Section 2?
-
Summer 2021Family Feud: A Cautionary Tale of the Costs, Risks, and Uncertainty of Minority-Shareholder Litigation
-
July 23, 2021Financial Daily Dose 7.23.2021 | Top Story: Amazon Abruptly Drops Mandatory Arbitration Requirement
-
July 22, 2021Financial Daily Dose 7.22.2021 | Top Story: Drug Companies Strike $26B Deal with State AGs Over Opioid Crisis
-
July 21, 2021Financial Daily Dose 7.21.2021 | Top Story: White House Names Google Critic Kanter to Lead DOJ Antitrust Division
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
GENERICally Speaking Spring 2021
The Spring 2021 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
A few of the relevant court decisions highlighted in this issue:
- Takeda Pharm. Co. Ltd. v. Torrent Pharms. Ltd.
Nesina® (alogliptin)
The district court did not commit clear error in its finding that a skilled artisan would not have been motivated to make defendants’ proposed scaffold and isosteric replacements with a reasonable expectation of success. - AstraZeneca AB v. Mylan Pharms. Inc.
Symbicort® (budesonide and formoterol fumarate dihydrate)
The patents-in-suit are not invalid as obvious because defendant failed to show it would have been obvious to select and combine the elements of the claimed invention, and because certain prior art actually taught away from the claimed invention. - Horizon Medicines LLC v. Dr. Reddy’s Labs., Inc.
Vimovo® (naproxen and esomeprazole magnesium)
The court denied summary judgment of invalidity on the basis of issue preclusion when the defendant could not show that the identical issue was previously adjudicated.
Relevant ANDA Updates highlighted in this issue:
Reported settlements in federal district court cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
Symbicort® (budesonide and formoterol fumarate dihydrate)
Vimovo® (naproxen and esomeprazole magnesium)
Nesina® (alogliptin)
Subscribe to our quarterly GENERICally Speaking Update.
Subscribe Now
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.